Vitamin intervention for stroke prevention

Journal of the Neurological Sciences

Volumn 203-204, Issue , 2002, Pages 121-124

  Toole, James F ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Folic acid; Methionine loading test; Pyridoxine; Stroke prevention; Vitamin B12; Vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE;

ADULT; AUSTRALIA; BRAIN INFARCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; INFORMED CONSENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; CEREBROVASCULAR ACCIDENT; DIET; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; RECURRENCE; RISK FACTORS; VITAMIN B 12; VITAMIN B 6; VITAMINS;

EID: 0037111444     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00265-4     Document Type: Conference Paper

References (12)

1. Williams G.R., Jiang J.G., Matchar D.B., Samsa G.P. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 30:1999;2523-2528.
2. Petty G.W., Brown R.D. Jr., Whisnant J.P., Sicks J.D., O'Fallon W.M., Wiebers D.O. Ischemic Stroke subtypes: a population-based study of functional outcome, survival and recurrence. Stroke. 31:2000;1062-1068.
3. Malinow M.R. H(e) and arterial occlusive diseases. J. Intern. Med. 236:1994;603-617.
4. Peterson J.C., Spence J.D. Vitamins and progression of atherosclerosis in patients with hyper-homocyst(e)inemia. Lancet. 351:1998;263.
5. Graham I.M., Daly L., Refsum H.et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 277:1997;1775-1781.
6. Nygård O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-236.
7. Bots M.L., Launer L.J., Lindermans J., Hoes A.W., Hofman A., Witteman J.C.M.et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study. Arch. Intern. Med. 159:1999;38-44.
8. van Dijk E.W., Vermeer S.E., den Heijer T. Homocysteine and cerebral white matter lesions: the Rotterdam scan study. Stroke. 32:2001;321-d.
9. Stampfer M.J., Malinow M.R. Can lowering homocysteine levels reduce cardiovascular risk? [Editorial] N. Engl. J. Med. 332:1995;328-329.
10. http://www.health.wa.gov.ua/VITATOPS
11. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J. Cardiovasc. Risk. 5:1998;249-255.
12. Spence J.D.et al. for the VISP Investigators Vitamin intervention for stroke prevention (VISP) trial: rationale and design. Neuroepidemiology. 20:2001;16-25.